港股異動丨康哲藥業(0867.HK)漲近5%欲創新高 創新藥亞甲藍腸溶緩釋片中國IND申請獲受理
格隆匯6月2日丨康哲藥業(0867.HK)拉昇漲4.89%,報20.6港元有望挑戰新高價,總市值達508億港元。6月1日,康哲藥業重磅創新藥亞甲藍腸溶緩釋片中國IND申請獲得國家藥品監督管理局藥品審評中心受理,該產品已於2020年8月獲歐洲藥品管理局批准以LumeblueTM商品名上市。亞甲藍腸溶緩釋片是一種用於診斷的口服藥物,通過增強接受篩查或監測結腸鏡檢查的成年患者結直腸病變的可視化,有助於提高結直腸癌或癌前病變的檢出率。在常規結腸鏡檢查步驟中添加亞甲藍腸溶緩釋片可提高診斷敏感性,為廣大患者帶來潛在益處,產品市場前景可期。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.